These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 29509313)

  • 1. Creutzfeldt astrocytes may be seen in IDH-wildtype glioblastoma and retain expression of DNA repair and chromatin binding proteins.
    Ballester LY; Boghani Z; Baskin DS; Britz GW; Olsen R; Fuller GN; Powell SZ; Cykowski MD
    Brain Pathol; 2018 Nov; 28(6):1012-1019. PubMed ID: 29509313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Granular cell astrocytoma: an aggressive IDH-wildtype diffuse glioma with molecular genetic features of primary glioblastoma.
    Vizcaino MA; Palsgrove DN; Yuan M; Giannini C; Cabrera-Aldana EE; Pallavajjala A; Burger PC; Rodriguez FJ
    Brain Pathol; 2019 Mar; 29(2):193-204. PubMed ID: 30222900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IDH-wild type glioblastomas featuring at least 30% giant cells are characterized by frequent RB1 and NF1 alterations and hypermutation.
    Barresi V; Simbolo M; Mafficini A; Martini M; Calicchia M; Piredda ML; Ciaparrone C; Bonizzato G; Ammendola S; Caffo M; Pinna G; Sala F; Lawlor RT; Ghimenton C; Scarpa A
    Acta Neuropathol Commun; 2021 Dec; 9(1):200. PubMed ID: 34952640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis.
    Suwala AK; Stichel D; Schrimpf D; Kloor M; Wefers AK; Reinhardt A; Maas SLN; Kratz CP; Schweizer L; Hasselblatt M; Snuderl M; Abedalthagafi MSJ; Abdullaev Z; Monoranu CM; Bergmann M; Pekrun A; Freyschlag C; Aronica E; Kramm CM; Hinz F; Sievers P; Korshunov A; Kool M; Pfister SM; Sturm D; Jones DTW; Wick W; Unterberg A; Hartmann C; Dodgshun A; Tabori U; Wesseling P; Sahm F; von Deimling A; Reuss DE
    Acta Neuropathol; 2021 Jan; 141(1):85-100. PubMed ID: 33216206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid progression to glioblastoma in a subset of IDH-mutated astrocytomas: a genome-wide analysis.
    Richardson TE; Snuderl M; Serrano J; Karajannis MA; Heguy A; Oliver D; Raisanen JM; Maher EA; Pan E; Barnett S; Cai C; Habib AA; Bachoo RM; Hatanpaa KJ
    J Neurooncol; 2017 May; 133(1):183-192. PubMed ID: 28421459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mismatch repair proteins PMS2 and MLH1 can further refine molecular stratification of IDH-mutant lower grade astrocytomas.
    Yang RR; Li KK; Zhang ZY; Chan AK; Wang WW; Chan DT; Li WC; Liu XZ; Li FC; Chen H; Ng HK; Mao Y; Shi ZF
    Clin Neurol Neurosurg; 2021 Sep; 208():106882. PubMed ID: 34428613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Widely metastatic glioblastoma with BRCA1 and ARID1A mutations: a case report.
    Umphlett M; Shea S; Tome-Garcia J; Zhang Y; Hormigo A; Fowkes M; Tsankova NM; Yong RL
    BMC Cancer; 2020 Jan; 20(1):47. PubMed ID: 31959133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Partial resection offers an overall survival benefit over biopsy in MGMT-unmethylated IDH-wildtype glioblastoma patients.
    Hallaert G; Pinson H; Vanhauwaert D; Van den Broecke C; Van Roost D; Boterberg T; Kalala JP
    Surg Oncol; 2020 Dec; 35():515-519. PubMed ID: 33152608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differentiating between glioblastomas with and without isocitrate dehydrogenase gene mutation by findings on conventional magnetic resonance images.
    Shimizu T; Matsushima S; Fukasawa N; Akasaki Y; Mori R; Ojiri H
    J Clin Neurosci; 2020 Jun; 76():140-144. PubMed ID: 32291242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SMARCAL1 loss and alternative lengthening of telomeres (ALT) are enriched in giant cell glioblastoma.
    Brosnan-Cashman JA; Davis CM; Diplas BH; Meeker AK; Rodriguez FJ; Heaphy CM
    Mod Pathol; 2021 Oct; 34(10):1810-1819. PubMed ID: 34103668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of immunobiologic markers in primary and recurrent glioblastoma.
    Rahman M; Kresak J; Yang C; Huang J; Hiser W; Kubilis P; Mitchell D
    J Neurooncol; 2018 Apr; 137(2):249-257. PubMed ID: 29302887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. "De novo replication repair deficient glioblastoma, IDH-wildtype" is a distinct glioblastoma subtype in adults that may benefit from immune checkpoint blockade.
    Hadad S; Gupta R; Oberheim Bush NA; Taylor JW; Villanueva-Meyer JE; Young JS; Wu J; Ravindranathan A; Zhang Y; Warrier G; McCoy L; Shai A; Pekmezci M; Perry A; Bollen AW; Phillips JJ; Braunstein SE; Raleigh DR; Theodosopoulos P; Aghi MK; Chang EF; Hervey-Jumper SL; Costello JF; de Groot J; Butowski NA; Clarke JL; Chang SM; Berger MS; Molinaro AM; Solomon DA
    Acta Neuropathol; 2023 Dec; 147(1):3. PubMed ID: 38079020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic characterization of gliomas arising in patients with multiple sclerosis.
    Khalil A; Serracino H; Damek DM; Ney D; Lillehei KO; Kleinschmidt-DeMasters BK
    J Neurooncol; 2012 Sep; 109(2):261-72. PubMed ID: 22547311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insular primary glioblastomas with IDH mutations: Clinical and biological specificities.
    Hata N; Hatae R; Yoshimoto K; Murata H; Kuga D; Akagi Y; Sangatsuda Y; Suzuki SO; Iwaki T; Mizoguchi M; Iihara K
    Neuropathology; 2017 Jun; 37(3):200-206. PubMed ID: 28116838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of p53 mutations in proliferating vascular cells in glioblastoma multiforme.
    Kawasoe T; Takeshima H; Yamashita S; Mizuguchi S; Fukushima T; Yokogami K; Yamasaki K
    J Neurosurg; 2015 Feb; 122(2):317-23. PubMed ID: 25415071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low MGMT digital expression is associated with a better outcome of IDH1 wildtype glioblastomas treated with temozolomide.
    Gomes I; Moreno DA; Dos Reis MB; da Silva LS; Leal LF; Gonçalves GM; Pereira CA; Oliveira MA; de Medeiros Matsushita M; Reis RM
    J Neurooncol; 2021 Jan; 151(2):135-144. PubMed ID: 33400009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53, mdm2, EGFR, and msh2 expression in paired initial and recurrent glioblastoma multiforme.
    Stark AM; Witzel P; Strege RJ; Hugo HH; Mehdorn HM
    J Neurol Neurosurg Psychiatry; 2003 Jun; 74(6):779-83. PubMed ID: 12754350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic and epigenetic landscape of IDH-wildtype glioblastomas with FGFR3-TACC3 fusions.
    Mata DA; Benhamida JK; Lin AL; Vanderbilt CM; Yang SR; Villafania LB; Ferguson DC; Jonsson P; Miller AM; Tabar V; Brennan CW; Moss NS; Sill M; Benayed R; Mellinghoff IK; Rosenblum MK; Arcila ME; Ladanyi M; Bale TA
    Acta Neuropathol Commun; 2020 Nov; 8(1):186. PubMed ID: 33168106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Epigenetic Regulator Jumonji Domain-Containing Protein 6 (JMJD6) Is Highly Expressed but Not Prognostic in IDH-Wildtype Glioblastoma Patients.
    Rosager AM; Dahlrot RH; Sørensen MD; Bangsø JA; Hansen S; Kristensen BW
    J Neuropathol Exp Neurol; 2022 Jan; 81(1):54-60. PubMed ID: 34875075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IDH-wildtype glioblastomas and grade III/IV IDH-mutant gliomas show elevated tracer uptake in fibroblast activation protein-specific PET/CT.
    Röhrich M; Loktev A; Wefers AK; Altmann A; Paech D; Adeberg S; Windisch P; Hielscher T; Flechsig P; Floca R; Leitz D; Schuster JP; Huber PE; Debus J; von Deimling A; Lindner T; Haberkorn U
    Eur J Nucl Med Mol Imaging; 2019 Nov; 46(12):2569-2580. PubMed ID: 31388723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.